No Data
Tofflon Science and Technology Group (300171.SZ): Currently, there are no production bases in Southeast Asia.
On March 4, Gelonghui reported that Tofflon Science and Technology Group (300171.SZ) stated on the investor interaction platform that the company has been a pioneer in exporting pharmaceutical equipment in China. Since establishing its international marketing division in 2004, it has strengthened its marketing network in international markets, and its products have been sold to more than 50 countries and regions globally, laying a solid customer foundation in the process of globalization. The company currently has no production base in Southeast Asia.
Returns On Capital At Tofflon Science and Technology Group (SZSE:300171) Have Hit The Brakes
Tofflon Science and Technology Group (300171.SZ): The company actively learns and utilizes DeepSeek.
On February 21, Galunhui reported that Tofflon Science and Technology Group (300171.SZ) stated on the investor interaction platform that the company is actively learning and utilizing DeepSeek, embracing advanced productivity tools to enhance operational efficiency, reduce corporate costs, and work hard to create value for Shareholders.
Tofflon Science and Technology Group (300171.SZ): Can provide Global pharmaceutical companies with integrated intelligent solutions for equipment + consumables + engineering.
On February 12, Glonghui reported that Tofflon Science and Technology Group (300171.SZ) stated on the investor interaction platform that the company has been deeply involved in the Biomedical Industry for over thirty years, adhering to the mission of "providing professional technical services for Biomedical" and is committed to becoming a provider of smart pharmaceutical factories. The company can offer Global pharmaceutical enterprises integrated smart solutions that include equipment, consumables, and engineering.
Tofflon Science and Technology Group Co., Ltd.'s (SZSE:300171) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Tofflon Science and Technology Group to Co-Invest 200 Million Yuan in Biopharmaceutical M&A Fund
Benign Growth For Tofflon Science and Technology Group Co., Ltd. (SZSE:300171) Underpins Stock's 26% Plummet
